Live Breaking News & Updates on Shakti Narayan

Stay updated with breaking news from Shakti narayan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Accent Therapeutics Announces $75 Million Series C Financing to Advance Small Molecule Precision Cancer Therapies

/PRNewswire/ Accent Therapeutics, a biopharmaceutical company pioneering a new class of small molecule precision cancer therapies, today announced the. ....

Shakti Narayan , Naveen Krishnan , Mark Foundation For Cancer Research , Company Board Of Directors , Jjdc Inc , Column Group , Atlas Venture , Bristol Myers Squibb , Mirae Asset Capital Life Science , Accent Therapeutics , Mirae Asset Capital , Mirae Asset Venture Investment , Johnson Innovation , Droia Ventures , Abbvie Ventures , Mark Foundation , Cancer Research , Timefolio Capital , Managing Director , Mirae Asset Capital Life ,

Accent Therapeutics Raises $75M in Series C Funding

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time! ....

Shakti Narayan , Naveen Krishnan , Jjdc Inc , Atlas Venture , Mark Foundation For Cancer Research , Column Group , Company Board Of Directors , Bristol Myers Squibb , Accent Therapeutics , Mirae Asset Capital Life Science , Mirae Asset Capital , Mirae Asset Venture Investment , Johnson Innovation , Droia Ventures , Abbvie Ventures , Mark Foundation , Cancer Research , Timefolio Capital , Managing Director ,

Pharmas back Accent's plan to make RNA-targeting cancer drugs

BioPharma ....

United States , South Korea , South Korean , Shakti Narayan , Naveen Krishnan , Bristol Myers Squibb , Mirae Asset Financial Group , Accent Therapeutics , Mirae Asset Capital Life Science ,

Ipsen : adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3 -Today at 10:52 am

Ipsen adds another program into its pre-clinical R&D Oncology pipeline through an exclusive worldwide collaboration with Accent Therapeutics, targeting the RNA modifying protein, METTL3

. ....

United States , Oumin Shi , P Ann Boriack Sjodin , Zacharya Gurard Levin , Scott Ribich , Ipsen Euronext , Roberta Copeland , Xiaoquin Lu , Shakti Narayan , Jeffreyl Hirsch , Christelle Huguet , Quanxiang Zeng , Benjamind Wheeler , Michaeld Scholle , Yong Li , Shanem Buker , Wei Wang , Qi Wang , Early Development , American Cancer Society , Head Of Research , Accent Therapeutics , Senior Vice President , External Innovation , Chief Executive Officer , Acute Myeloid ,

Accent Therapeutics Presents Data Supporting DHX9 Inhibition as a Novel Therapeutic Modality at American Association for Cancer Research (AACR) Annual Meeting 2023

/PRNewswire/ Accent Therapeutics, a biopharmaceutical company developing breakthrough, oncology-focused small molecule therapies that target RNA-modifying. ....

United States , Orange County Convention Center , P Ann Boriack Sjodin , Shakti Narayan , Kennethw Duncan , E Allen Sickmier , Deepali Gotur , Matthewh Daniels , Kevin Knockenhauer , David Brennan , Chuang Lu , Stephenj Blakemore , Roberta Copeland , Shanem Buker , Scott Ribich , Briana Sparling , Julie Liu , Jennifer Castro , Jie Wu , Cancer Research , American Association For Cancer Research , American Association , Annual Meeting , Chief Scientific Officer , Chief Executive Officer , Accent Therapeutics ,